Article Details
Retrieved on: 2020-12-21 13:30:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
AzurRX BioPharma Inc. (NASDAQ:AZRX) has announced the dosing of the first two patients in Turkey for the Phase 2 study. The study is evaluating ...
Article found on: biopharmajournal.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here